Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New obesity drug shows promise in phase 2 fat-loss trial

NCT ID NCT07169942

First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 33 times

Summary

This study tests a new medication called aleniglipron (GSBR-1290) to see if it helps people with obesity lose body fat. About 71 adults with a BMI of 30 or higher will receive either the drug or a placebo for 40 weeks. The main goal is to measure changes in total body fat using a special scan.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY, OVERWEIGHT, OR CHRONIC WEIGHT MANAGEMENT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Research Site

    Phoenix, Arizona, 85020, United States

  • Research Site

    Chicago, Illinois, 60602, United States

  • Research Site

    Richfield, Minnesota, 55423, United States

  • Research Site

    City of Saint Peters, Missouri, 63303, United States

  • Research Site

    Rochester, New York, 14609, United States

  • Research Site

    Wilmington, North Carolina, 28401, United States

  • Research Site

    Norman, Oklahoma, 73069, United States

  • Research Site

    Moncks Corner, South Carolina, 29461, United States

  • Research Site

    North Charleston, South Carolina, 29405, United States

  • Research Site

    Austin, Texas, 78704, United States

  • Research Site

    San Antonio, Texas, 78240, United States

Conditions

Explore the condition pages connected to this study.